Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 838 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Grieving for Your Old Life After Cancer September 10, 2020 Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows December 13, 2018 Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma October 25, 2019 Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... January 11, 2022 Load more HOT NEWS Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... How to Talk About Advanced Cancer Care Planning: An Expert Discussion
